Healthy People 2010 targets & levels achieved in 2000 figure hp.1

Slides:



Advertisements
Similar presentations
Cardiovascular Implantable Electronic Device Leads & Arteriovenous Hemodialysis Access Theodore F. Saad, MD Nephrology Associates, PA Christiana Care Health.
Advertisements

Chapter 4: Hospitalization 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
The State of CKD, ESRD and Mortality in the First Year on Dialysis: Are We Doing Enough? Allan J. Collins, MD, FACP Professor of Medicine University of.
Chapter 3: Clinical Indicators and Preventive Care 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Chapter 2: Healthy People A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Vol 2 Figure 1.1 Trends in the number of incident cases of ESRD, in thousands, by modality, in the U.S. population, Data Source: Reference.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Infections in the dialysis population: A major communicable disease issue! Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
Healthy People 2010 Focus Area 4
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 11: Costs of ESRD.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 10: Dialysis Providers.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 5: Hospitalization.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.
Healthy People 2010 Focus Area 4: Chronic Kidney Disease Progress Review September 21, 2006.
USRDS USRDS 2002 adr Period prevalent ESRD patient, deaths, & ESRD expenditures figure 12.1.
USRDS 2000 ADR USRDS Hepatitis B vaccine & antibody among patients & unit staff figure 9.1, dialysis patients, 1997, by network.
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
USRDS 2000 ADR USRDS Cadaveric donations by gender & race figure 7.1, patients aged
Primary Cause of Kidney Failure in new ESRD patients at initiation, by ethnicity figure 2.1, combined.
2016 Annual Data Report, Vol 2, ESRD, Ch 5
2016 Annual Data Report, Vol 2, ESRD, Ch 8
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Figure 10.1 Dialysis unit counts, by unit affiliation, 2011–2014
First-year death rates by modality figure 8
Percent of patients receiving influenza vaccinations figure 5
Odd ratio of developing kidney failure figure 1
Patient populations by study group figure 10
ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.
Mortality rates in incident ESRD patients figure 9
Volume 2: End-Stage Renal Disease
2016 Annual Data Report, Vol 1, CKD, Ch 2
2017 Annual Data Report Healthy People 2020.
Summary of the 2013 ERA-EDTA Registry Annual Report
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Volume 2: End-Stage Renal Disease
Number of transplants, by donor type figure 8.1
Chapter 7: ESRD among Children, Adolescents, and Young Adults
Volume 2: End-Stage Renal Disease Chapter 6: Transplantation
December 31st point prevalent counts by modality figure 3.1
UK Renal Registry 18th Annual Report
Figure 2.1 First-year hospital admission rates among incident dialysis patients, by annual & monthly cohorts Patients aged 18 years or older. Peer Report Dialysis.
2016 Annual Data Report, Vol 2, ESRD, Ch 4
Hospital admissions per patient, by modality figure 5
UK Renal Registry 9th Annual Report 2006
CHAPTER 5 Paediatric Renal Replacement Therapy
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
2016 Annual Data Report, Vol 1, CKD, Ch 3
Hemoglobin, EPO, & Iron dose figure 4
2018 Annual Data Report Volume 3: Healthy People 2020
Volume 2: End-Stage Renal Disease Chapter 6: Transplantation
Volume 2: End-Stage Renal Disease
CHAPTER 1 All Renal Replacement Therapy In Malaysia
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Type of vascular access and mortality in U.S. hemodialysis patients
Anne M. Butler, PhD, Andrew F. Olshan, PhD, Abhijit V
Cause Specific Death Rates for All Dialysis Patients
Survival advantage in Asian American end-stage renal disease patients1
Volume 67, Issue 4, Pages (April 2005)
American Journal of Kidney Diseases
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
The Use of Vaccines in Adult Patients With Renal Disease
Renal replacement therapy in Latin America
Worldwide incidence of ESRD figure 12.1, per million population
Presentation transcript:

Healthy People 2010 targets & levels achieved in 2000 figure hp.1

Trends in ESRD incident rates figure hp Trends in ESRD incident rates figure hp.2, incident ESRD patients, adjusted for age, gender, & race

ESRD incident rates, by year table hp ESRD incident rates, by year table hp.a, rate per million population, incident ESRD patients

Trends in ESRD incident rates figure hp Trends in ESRD incident rates figure hp.3, incident ESRD patients, by age & race/ethnicity

Trends in ESRD incident rates, by primary diagnosis, & in rates of diabetes in the general population figure hp.4, adjusted for age, gender, & race

Trends in cardiovascular mortality rates among ESRD patients figure hp Trends in cardiovascular mortality rates among ESRD patients figure hp.5, period prevalent patients

Cardiovascular mortality rates in ESRD patients, by modality table hp Cardiovascular mortality rates in ESRD patients, by modality table hp.b, deaths per 1,000 patient years at risk, period prevalent ESRD patients

Trends in all-cause & cardiovascular mortality rates in ESRD patients figure hp.6, period prevalent ESRD patients, by race/ethnicity illi illi lla lla

Trends in rates of cardiovascular disease in ESRD patients figure hp Trends in rates of cardiovascular disease in ESRD patients figure hp.7, deaths per 1,000 patient years, period prevalent ESRD patients illi illi lla lla

Trends in arteriovenous fistula use in hemodialysis patients, by data source figure hp.8, incident hemodialysis patients, 1998-1999 combined Symbols D% from previous year illi illi lla lla

Arteriovenous fistula use in incident hemodialysis patients, by data source table hp.c, percent of patients illi illi lla lla

Trends in arteriovenous fistula use in prevalent hemodialysis patients, by age & race/ethnicity figure hp.9, period prevalent hemodialysis patients illi illi lla lla

Trends in access fistula use in prevalent hemodialysis pts, by gender & diabetic status figure hp.10, period prevalent hemodialysis patients illi illi lla lla

Trends in the percent of ESRD patients receiving influenza vaccinations figure hp.11 illi illi lla lla

Percent of ESRD patients receiving influenza & pneumonia vaccinations, by year table hp.d, percent of patients vaccinated illi illi lla lla

Trends in the percent of ESRD patients receiving influenza vaccinations, by age & race/ethnicity figure hp.12 illi illi lla lla

Pneumococcal pneumonia vaccinations in ESRD patients, by age & race/ethnicity figure hp.13, for 1995-1996 period illi illi lla lla

Trends in the percent of dialysis patients on the transplant waiting list figure hp.14, period prevalent hemodialysis patients illi illi lla lla

Percent of patients on the transplant waiting list, by year table hp.e illi illi lla lla

Dialysis pts on the transplant waiting list, by age, gender, race/ethnicity, & primary diagnosis table hp.15 illi illi lla lla

Dialysis pts on the transplant waiting list, by age, gender, race/ethnicity, & primary diagnosis table hp.15 (cont.) illi illi lla lla

Percent of dialysis patients receiving a transplant within 3 years of initiation of therapy figure hp.16 illi illi lla lla

Percent of dialysis patients receiving a transplant within 3 years of initiation, by year table hp.f illi illi lla lla

Dialysis patients receiving a tx within 3 years, by age, gender, race/ethnicity, & diagnosis figure hp.17 illi illi lla lla

Dialysis patients receiving a tx within 3 years, by age, gender, race/ethnicity, & diagnosis figure hp.17 (cont.) illi illi lla lla

Bars: Rat per million population Trends in incident rates of ESRD due to diabetes figure hp.18, incident ESRD patients, adjusted for age, gender, & race Bars: Rat per million population illi illi lla lla

Incident rates of ESRD due to diabetes, by modality & year table hp Incident rates of ESRD due to diabetes, by modality & year table hp.g, rate per million population, incident ESRD patients illi illi lla lla

Trends in incident rates of ESRD due to diabetes, by age figure hp Trends in incident rates of ESRD due to diabetes, by age figure hp.19, incident ESRD patients, adjusted for gender & race illi illi lla lla

Trends in incident rates of ESRD due to diabetes, by race/ethnicity figure hp.20, incident ESRD patients, adjusted for age & gender illi illi lla lla

Percent of diabetic patients receiving all 3 diabetic preventive health tests, by data source figure hp.21 General Medicare Pre-ESRD illi illi lla lla

Percent of diabetic patients receiving preventive health tests, by test type table hp.h, 1997-1999 illi illi lla lla

Diabetics receiving all 3 preventive health tests, by pt population, age, & race/ethnicity figure hp.22 illi illi lla lla

Diabetics receiving all 3 preventive health tests, by pt population, age, & race/ethnicity figure hp.22 (cont.) illi illi lla lla